Compare DexCom, Inc. (DXCM) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Nuscale Power Corporation — how do they compare? DexCom, Inc. trades at $77.61 (market cap $28.06B), while Nuscale Power Corporation trades at $7.57 (market cap $2.89B). The key difference: DexCom, Inc. is far larger — about 9.7× Nuscale Power Corporation's market cap, and DexCom, Inc. is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| DXCM | SMR | |
|---|---|---|
Market Cap | $28.06B | $2.89B |
Sector | Health | Utilities |
52-Week High | $89.53 | $53.43 |
52-Week Low | $54.84 | $8.35 |
Enterprise Value | $27.03B | $2.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
SMR (NuScale Power) trades at $7.83, down 8.85% on the day and near its 52-week lows. The stock faces significant fundamental challenges with negative net income margins (-2,066.55% in 2026) and consecutive earnings misses, though analyst sentiment remains mixed with a $12.25 consensus price target suggesting 56% upside. Technical indicators show bearish momentum with the price testing key support at $7.
The outlook hinges on NuScale's ability to commercialize its SMR technology amid growing AI power demand. While first-mover advantage and government support provide long-term potential, near-term risks include persistent operating losses, delayed revenue generation, and high cash burn requiring continued financing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
